|
1
|
Azer SA, Alsharafi AA. Can pharmacy students use Wikipedia as a learning resource? Critical assessment of articles on chemotherapeutic drugs. ADVANCES IN PHYSIOLOGY EDUCATION 2023; 47:333-345. [PMID: 36951631 DOI: 10.1152/advan.00212.2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 02/17/2023] [Accepted: 03/11/2023] [Indexed: 06/18/2023]
Abstract
Pharmacy students tend to use Wikipedia as a quick resource of knowledge. This study aimed to evaluate the accuracy of content and readability level of Wikipedia articles on chemotherapeutics, using quality and readability tools. Using the British National Formulary (BNF-2018) and ClinicalTrials.gov, we identified 188 chemotherapeutic drugs. We randomly selected 100 drugs with an Excel randomization program. The English Wikipedia was searched for the selected 100 drugs, and prints of the identified articles were obtained. Readability was calculated with an online instrument (http://www.readabilityformulas.com/). Articles were independently scored by two researchers using the modified DISCERN tool for content assessment. The modified DISCERN scores had a median value of 24 [interquartile range (IQR) = 7.5]. Two articles (2%) had good quality (DISCERN score 36-40), thirty-eight (38%) were moderate (DISCERN 26-35), and sixty (60%) were poor in score (DISCERN ≤25). The articles covered drug indications and most side effects. However, the majority lacked information on the routes of administration, contraindications, pharmacokinetics, and mechanisms of action. We found a correlation between DISCERN scores and number of edits (P value = 0.00033, R2 = 0.1238). The number of references varied from 2 to 150 (median= 17, IQR = 17). Several problems were identified in the lists of references and citations. Most articles lacked tables and figures. The readability of the articles was 14.35 ± 3.13, consistent with the readability level of university students. In conclusion, the Wikipedia articles on chemotherapeutic drugs were not written for professional pharmacy students. Although they matched the expected readability level of university students, most were incomplete and lacked essential information.NEW & NOTEWORTHY Pharmacy students use Wikipedia as a quick resource of knowledge. However, Wikipedia articles are not written for professional pharmacy students. The study shows that although Wikipedia articles on chemotherapeutic drugs matched the expected readability level of university students, most needed to be completed and lacked essential information.
Collapse
Affiliation(s)
- Samy A Azer
- Department of Medical Education, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Aya A Alsharafi
- College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
|
2
|
Bernardini A, Dueñas M, Martín-Soberon MC, Rubio C, Suarez-Cabrera C, Ruiz-Palomares R, Munera-Maravilla E, Lázaro S, Lodewijk I, Rueda D, Gómez-Sánchez D, Alonso-Gordoa T, Puente J, Pinto Á, González-Peramato P, Aguado C, Herrera M, López F, Martinez VMG, Morales L, Castellano D, Paramio JM, de Velasco G. Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer. Cancers (Basel) 2022; 14:cancers14020378. [PMID: 35053540 PMCID: PMC8773703 DOI: 10.3390/cancers14020378] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/28/2021] [Accepted: 12/29/2021] [Indexed: 02/01/2023] Open
Abstract
Simple Summary Few metastatic urothelial cancer patients achieve durable clinical benefit with vinflunine. Predictive biomarkers to help to identify better treatment strategies are extremely needed. The objective of this study was to identify molecular differences between extreme responders to vinflunine in urothelial cancer. Genomic and immune markers are potentially useful identifying patients that may achieve greater benefit with vinflunine. Abstract Background and Aims: Metastatic urothelial carcinoma (mUC) remains an incurable disease with limited treatment options after platinum-based chemotherapy and immune checkpoint blockade (ICB). Vinflunine has shown a modest increase in overall survival and remains a therapeutic option for chemo- and immunotherapy refractory tumours. However, biomarkers that could identify responding patients to vinflunine and possible alternative therapies after failure to treatment are still missing. In this study, we aimed to identify potential genomic biomarkers of vinflunine response in mUC patient samples and potential management alternatives. Methods: Formalin-fixed paraffin-embedded samples of mUC patients (n = 23) from three university hospitals in Spain were used for genomic targeted-sequencing and transcriptome (using the Immune Profile panel by NanoString) analyses. Patients who received vinflunine after platinum-based chemotherapy failure were classified in non-responders (NR: progressive disease ≤ 3 months; n= 11) or responders (R: response ≥ 6 months; n = 12). Results: Genomic characterization revealed that the most common alteration, TP53 mutations, had comparable frequency in R (6/12; 50%) and NR (4/11; 36%). Non-synonymous mutations in KTM2C (4/12; 33.3%), PIK3CA (3/12; 25%) and ARID2 (3/12; 25%) were predominantly associated with response. No significant difference was observed in tumour mutational burden (TMB) between R and NR patients. The NR tumours showed increased expression of diverse immune-related genes and pathways, including various interferon gamma-related genes. We also identified increased MAGEA4 expression as a potential biomarker of non-responding tumours to vinflunine treatment. Conclusions: Our data may help to identify potential genomic biomarkers of response to vinflunine. Moreover, tumours refractory to vinflunine showed immune signatures potentially associated with response to ICB. Extensive validation studies, including longitudinal series, are needed to corroborate these findings.
Collapse
Affiliation(s)
- Alejandra Bernardini
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - Marta Dueñas
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - María Cruz Martín-Soberon
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Departamento de Oncología Médica, Hospital 12 de Octubre, 28040 Madrid, Spain; (M.H.); (F.L.)
| | - Carolina Rubio
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - Cristian Suarez-Cabrera
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - Raquel Ruiz-Palomares
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
| | - Ester Munera-Maravilla
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - Sara Lázaro
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
| | - Iris Lodewijk
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - Daniel Rueda
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
| | - David Gómez-Sánchez
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
| | | | - Javier Puente
- Departamento de Oncología Médica, Hospital Clínico San Carlos, 28040 Madrid, Spain; (J.P.); (C.A.)
| | - Álvaro Pinto
- Departamento de Oncología Médica, Hospital La Paz, 28046 Madrid, Spain; (Á.P.); (P.G.-P.)
| | | | - Carlos Aguado
- Departamento de Oncología Médica, Hospital Clínico San Carlos, 28040 Madrid, Spain; (J.P.); (C.A.)
| | - Mercedes Herrera
- Departamento de Oncología Médica, Hospital 12 de Octubre, 28040 Madrid, Spain; (M.H.); (F.L.)
| | - Flora López
- Departamento de Oncología Médica, Hospital 12 de Octubre, 28040 Madrid, Spain; (M.H.); (F.L.)
| | - Victor M. G. Martinez
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
| | - Lucía Morales
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
| | - Daniel Castellano
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
- Departamento de Oncología Médica, Hospital 12 de Octubre, 28040 Madrid, Spain; (M.H.); (F.L.)
| | - Jesús M. Paramio
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Unidad de Oncología Molecular, CIEMAT, 28045 Madrid, Spain;
- Centro de Investigacion en Red de Cáncer CIBERONC, 28029 Madrid, Spain
- Correspondence: (J.M.P.); (G.d.V.)
| | - Guillermo de Velasco
- Instituto de Investigación i+12, Hospital University “12 de Octubre”, 28040 Madrid, Spain; (A.B.); (M.D.); (M.C.M.-S.); (C.R.); (C.S.-C.); (R.R.-P.); (E.M.-M.); (I.L.); (D.R.); (D.G.-S.); (V.M.G.M.); (L.M.); (D.C.)
- Departamento de Oncología Médica, Hospital 12 de Octubre, 28040 Madrid, Spain; (M.H.); (F.L.)
- Correspondence: (J.M.P.); (G.d.V.)
| |
Collapse
|
|
3
|
Mitra S, Prova SR, Sultana SA, Das R, Nainu F, Emran TB, Tareq AM, Uddin MS, Alqahtani AM, Dhama K, Simal-Gandara J. Therapeutic potential of indole alkaloids in respiratory diseases: A comprehensive review. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2021; 90:153649. [PMID: 34325978 DOI: 10.1016/j.phymed.2021.153649] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 07/01/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND Indole alkaloids are very promising for potential therapeutic purposes and appear to be particularly effective against respiratory diseases. Several experimental studies have been performed, both in vivo and in vitro, to evaluate the effectiveness of indole alkaloids for the management of respiratory disorders, including asthma, emphysema, tuberculosis, cancer, and pulmonary fibrosis. PURPOSE The fundamental objective of this review was to summarize the in-depth therapeutic potential of indole alkaloids against various respiratory disorders. STUDY DESIGN In addition to describing the therapeutic potential, this review also evaluates the toxicity of these alkaloids, which have been utilized for therapeutic benefits but have demonstrated toxic consequences. Some indole alkaloids, including scholaricine, 19-epischolaricine, vallesamine, and picrinine, which are derived from the plant Alstonia scholaris, have shown toxic effects in non-rodent models. METHODS This review also discusses clinical studies exploring the therapeutic efficacy of indole alkaloids, which have confirmed the promising benefits observed in vivo and in vitro. RESULTS The indole alkaloidal compounds have shown efficacy in subjects with respiratory diseases. CONCLUSION The available data established both preclinical and clinical studies confirm the potential of indole alkaloids to treat the respiratory disorders.
Collapse
Affiliation(s)
- Saikat Mitra
- Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
| | - Shajuthi Rahman Prova
- Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
| | - Sifat Ara Sultana
- Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
| | - Rajib Das
- Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
| | - Firzan Nainu
- Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi 90245, Indonesia
| | - Talha Bin Emran
- Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.
| | - Abu Montakim Tareq
- Department of Pharmacy, International Islamic University Chittagong, Chittagong 4318, Bangladesh
| | - Md Sahab Uddin
- Department of Pharmacy, Southeast University, Dhaka 1213, Bangladesh; Pharmakon Neuroscience Research Network, Dhaka 1207, Bangladesh
| | - Ali M Alqahtani
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, Uttar Pradesh, India
| | - Jesus Simal-Gandara
- Nutrition and Bromatology Group, Department of Analytical and Food Chemistry, Faculty of Food Science and Technology, University of Vigo - Ourense Campus, E32004 Ourense, Spain.
| |
Collapse
|
|
4
|
Agarwal G, Carcache PJB, Addo EM, Kinghorn AD. Current status and contemporary approaches to the discovery of antitumor agents from higher plants. Biotechnol Adv 2020; 38:107337. [PMID: 30633954 PMCID: PMC6614024 DOI: 10.1016/j.biotechadv.2019.01.004] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 01/03/2019] [Accepted: 01/07/2019] [Indexed: 12/13/2022]
Abstract
Higher plant constituents have afforded clinically available anticancer drugs. These include both chemically unmodified small molecules and their synthetic derivatives currently used or those in clinical trials as antineoplastic agents, and an updated summary is provided. In addition, botanical dietary supplements, exemplified by mangosteen and noni constituents, are also covered as potential cancer chemotherapeutic agents. Approaches to metabolite purification, rapid dereplication, and biological evaluation including analytical hyphenated techniques, molecular networking, and advanced cellular and animal models are discussed. Further, enhanced and targeted drug delivery systems for phytochemicals, including micelles, nanoparticles and antibody drug conjugates (ADCs) are described herein.
Collapse
Affiliation(s)
- Garima Agarwal
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States
| | - Peter J Blanco Carcache
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States
| | - Ermias Mekuria Addo
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States
| | - A Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
| |
Collapse
|
|
5
|
Lei X, Chen M, Huang M, Li X, Shi C, Zhang D, Luo L, Zhang Y, Ma N, Chen H, Liang H, Ye W, Zhang D. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization. Am J Cancer Res 2018; 8:384-398. [PMID: 29290815 PMCID: PMC5743555 DOI: 10.7150/thno.22222] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 10/13/2017] [Indexed: 01/18/2023] Open
Abstract
Vinca alkaloids, the well-known tubulin-binding agents, are widely used for the clinical treatment of malignant tumors. However, little attention has been paid to their vascular disrupting effects, and the underlying mechanisms remain largely unknown. This study aims to investigate the vascular disrupting effect and the underlying mechanisms of vinca alkaloids. Methods: The capillary disruption assay and aortic ring assay were performed to evaluate the in vitro vascular disrupting effect of desacetylvinblastine monohydrazide (DAVLBH), a derivate of vinblastine, and the in vivo vascular disrupting effect was assessed on HepG2 xenograft model using magnetic resonance imaging, hematoxylin and eosin staining and immunohistochemistry. Tubulin polymerization, endothelial cell monolayer permeability, western blotting and immunofluorescence assays were performed to explore the underlying mechanisms of DAVLBH-mediated tumor vascular disruption. Results: DAVLBH has potent vascular disrupting activity both in vitro and in vivo. DAVLBH disrupts tumor vessels in a different manner than classical tubulin-targeting VDAs; it inhibits microtubule polymerization, promotes the internalization of vascular endothelial cadherin (VE-cadherin) and inhibits the recycling of internalized VE-cadherin to the cell membrane, thus increasing endothelial cell permeability and ultimately resulting in vascular disruption. DAVLBH-mediated promotion of VE-cadherin internalization and inhibition of internalized VE-cadherin recycling back to the cell membrane are partly dependent on inhibition of microtubule polymerization, and Src activation is involved in DAVLBH-induced VE-cadherin internalization. Conclusions: This study sheds light on the tumor vascular disrupting effect and underlying mechanisms of vinca alkaloids and provides new insight into the molecular mechanism of tubulin-targeting VDAs.
Collapse
|
|
6
|
New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer. Biomed Pharmacother 2017; 96:659-666. [DOI: 10.1016/j.biopha.2017.10.041] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 10/08/2017] [Accepted: 10/09/2017] [Indexed: 12/22/2022] Open
|
|
7
|
Lee CT, Huang YW, Yang CH, Huang KS. Drug delivery systems and combination therapy by using vinca alkaloids. Curr Top Med Chem 2016; 15:1491-500. [PMID: 25877096 PMCID: PMC4997956 DOI: 10.2174/1568026615666150414120547] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Revised: 11/30/2014] [Accepted: 12/20/2014] [Indexed: 01/01/2023]
Abstract
Developing new methods for chemotherapy drug delivery has become a topic of great concern. Vinca alkaloids are among the most widely used chemotherapy reagents for tumor therapy; however, their side effects are particularly problematic for many medical doctors. To reduce the toxicity and enhance the therapeutic efficiency of vinca alkaloids, many researchers have developed strategies such as using liposome-entrapped drugs, chemical- or peptide-modified drugs, polymeric packaging drugs, and chemotherapy drug combinations. This review mainly focuses on the development of a vinca alkaloid drug delivery system and the combination therapy. Five vinca alkaloids (eg, vincristine, vinblastine, vinorelbine, vindesine, and vinflunine) are reviewed.
Collapse
Affiliation(s)
| | | | | | - Keng-Shiang Huang
- School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.
| |
Collapse
|
|
8
|
Khazir J, Riley DL, Pilcher LA, De-Maayer P, Mir BA. Anticancer Agents from Diverse Natural Sources. Nat Prod Commun 2014. [DOI: 10.1177/1934578x1400901130] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.
Collapse
Affiliation(s)
- Jabeena Khazir
- Department of Chemistry, University of Pretoria, Pretoria 0028, South Africa
| | - Darren L. Riley
- Department of Chemistry, University of Pretoria, Pretoria 0028, South Africa
| | - Lynne A. Pilcher
- Department of Chemistry, University of Pretoria, Pretoria 0028, South Africa
| | - Pieter De-Maayer
- Centre for Microbial Ecology and Genomics, Department of Genetics, University of Pretoria, Pretoria 0028, South Africa
- Genomics Research Institute, University of Pretoria, Pretoria 0028, South Africa
| | - Bilal Ahmad Mir
- Centre for Microbial Ecology and Genomics, Department of Genetics, University of Pretoria, Pretoria 0028, South Africa
- Genomics Research Institute, University of Pretoria, Pretoria 0028, South Africa
| |
Collapse
|
|
9
|
Butler MS, Robertson AAB, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep 2014; 31:1612-61. [DOI: 10.1039/c4np00064a] [Citation(s) in RCA: 383] [Impact Index Per Article: 38.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The 25 Natural Product (NP)-derived drugs launched since 2008 and the 100 NP-derived compounds and 33 Antibody Drug Conjugates (ADCs) in clinical trials or in registration at the end of 2013 are reviewed.
Collapse
Affiliation(s)
- Mark S. Butler
- Division of Chemistry and Structural Biology
- Institute for Molecular Bioscience
- The University of Queensland
- Brisbane, Australia
| | - Avril A. B. Robertson
- Division of Chemistry and Structural Biology
- Institute for Molecular Bioscience
- The University of Queensland
- Brisbane, Australia
| | - Matthew A. Cooper
- Division of Chemistry and Structural Biology
- Institute for Molecular Bioscience
- The University of Queensland
- Brisbane, Australia
| |
Collapse
|
|
10
|
Cortes J, Montero AJ, Glück S. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev 2011; 38:143-51. [PMID: 21550727 DOI: 10.1016/j.ctrv.2011.03.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Revised: 03/23/2011] [Accepted: 03/28/2011] [Indexed: 11/17/2022]
Abstract
BACKGROUND Microtubule-targeted agents are one of the most common classes of chemotherapeutic drug for the treatment of breast cancer. Limitations of current microtubule-targeted agents such as primary or secondary resistance of cancer cells and side effects like neuropathy prompted the discovery and introduction of newer more effective drugs. This review aims to provide a summary of the novel halichondrin B analog eribulin mesylate (E7389) and illustrate where it is placed in the treatment arena versus other agents that are approved or are currently in various stages of clinical development. METHODS Preclinical and clinical trial (phases I-III) data for eribulin were obtained from scientific journals and meeting abstracts, posters, and oral presentations. The use of current and other emerging microtubule inhibiting agents in breast cancer was also surveyed and briefly reviewed. RESULTS Eribulin mesylate at a dose of 1.4 mg/m(2) given on days 1 and 8 of a 21-day cycle increased overall survival in patients with metastatic breast cancer (MBC). Neutropenia, fatigue, alopecia, nausea and anemia were common adverse events (AEs) associated with eribulin in clinical studies. A low incidence of peripheral neuropathy was also associated with eribulin in clinical studies (21-26%). Other emerging microtubule targeted agents, such as vinflunine and larotaxel, also reported efficacy in patients with MBC who had received prior chemotherapy, with grade 3/4 neutropenia being the most common AEs for both agents. CONCLUSIONS Eribulin mesylate offers clinical activity in advanced breast cancer through improved overall survival, its favorable side-effect profile and convenience of preparation and administration.
Collapse
Affiliation(s)
- Javier Cortes
- Department of Oncology, Vall d´Hebron University Hospital, Barcelona, Spain.
| | | | | |
Collapse
|